Q3 2025 Abeona Therapeutics Inc Earnings Call Transcript

Nov 12, 2025 / 01:30 PM GMT

Release Date Price: $4.94 (+18.47%)

Transcript 10-Q8-K

Key Points

Positve

Abeona Therapeutics Inc (ABEO) has made significant operational progress in scaling the ZivaSkin commercial launch to meet growing patient demand.
The company has strategically expanded its qualified treatment center network, with the activation of Children's Hospital Colorado, bringing the total to three centers.
Abeona Therapeutics Inc (ABEO) has established broad market access, with positive coverage decisions from major commercial payers and all 51 state Medicaid programs.
The company has a robust cash position of $207.5 million, providing financial flexibility for the ZivaSkin commercial launch.
The gene therapy program for X-linked retinoschisis, ABO 503, has been selected for the FDA Rare Disease Endpoint Advancement pilot program, potentially accelerating its development.

Negative

There was a delay in the first patient treatment due to a performance issue in a release assay, causing a temporary pause in patient biopsies.
The rapid sterility assay delivered false positive results, leading to the rejection of a drug product batch.
The company had to pause collecting additional patient biopsies to optimize the release assay, delaying patient treatments to the fourth quarter of 2025.
Research and development spending decreased significantly, which may impact future innovation and development.
The net loss for the third quarter of 2025 was $5.2 million, although it was an improvement from the previous year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ABEO.OQ - Abeona Therapeutics Inc
Q3 2025 Abeona Therapeutics Inc Earnings Call
Nov 12, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone, and welcome to the Abbona Therapeutics 3rd quarter 2025 conference call.

At this time, all participants are in a listen-only mode, and the floor will be open for questions following the presentation.

If anyone should require operator assistance during this conference, please press 0 on your phone keypad. Please note this conference is being recorded.

I will now turn the conference over to your host, Gregory Ginn, VP of Investor relations and corporate communications at Aiona. Gregg, the floor is yours.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.